Australia's Dimerix rises on nod for development plan of potential paediatric drug

Dimerix

05/07/2023 03:17

** Shares of Dimerix Ltd  DXB.AX  rise as much as 13.6% to
A$0.092, their highest level since May 5
    ** Shares on track for fourth day of consecutive gains
    ** Clinical-stage biopharmaceutical co receives approval for
paediatric investigation plan from the Paediatric Committee of
the European Medicines Agency
    ** Says approval received for the development of DMX-200 
    ** DMX-200 is being developed by co as potential treatment
for children with focal segmental glomerulosclerosis kidney
disease
    ** About 2.6 mln shares change hands compared to 30-day
average trading volume of 990,898 shares 
    ** DXB down 43.2% YTD, as of last close 
   

 (Reporting by John Biju in Bengaluru)
 ((John.Biju@thomsonreuters.com;))